RESULTS	During the follow-up , significantly fewer subjects primed with the HB-AS04 vaccine needed a booster dose as a consequence of anti-HBs loss below seroprotective levels ( 11/62 subjects in the HB-AS04 group vs. 22/57 subjects in the standard vaccine group , respectively , P = 0.014 ) .\